Friday 6-20-2014 Amgen Inc (AMGN) $AMGN opened at

Friday 6-20-2014 Amgen Inc (AMGN) $AMGN opened at 118.23 hitting the high price of 121.00 and a day low of 117.83 with a total volume of 7,326,514. AMGN had a previous close of 117.85 and has been seeing an average volume of 2,571,800.

Overall Average: 64% Buy

Recent stock forum discussions about AMGN http://investorshangout.com/search?q=AMGN&...mp;yt0=Go!

Final Glance: Biotechnology companies
AP - Fri Jun 20, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading: (full story)

Midday Glance: Biotechnology companies
AP - Fri Jun 20, 12:26PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.: (full story)

Early Glance: Biotechnology companies
AP - Fri Jun 20, 9:35AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)

Amgen Rises 1.14% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jun 18, 4:13PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $115.50 to a high of $117.56. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $116.91 on volume of 2.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)

Look for Shares of Amgen to Potentially Pullback after Yesterday's 1.14% Rise
Comtex SmarTrend(R) - Wed Jun 18, 4:13PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $115.50 to a high of $117.56. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $116.91 on volume of 2.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)

Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue
M2 - Wed Jun 18, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dj8ssn/vital_signs) has announced the addition of the "Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue" report to their offering. This issue of Vital Signs, released on February 28, 2014, discusses three M&A transactions this month by Nestle, Myriad Genetics, and Fludigm' and what these deals mean for the industry. Additionally, Illumina's first stab at personalized medicine through a partnership with Amgen is explored. For more information visit http://www.researchandmarkets.com/research/dj...ital_signs About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. (full story)

3 Undervalued Amgen Growth Opportunities to Watch
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Jun 16, 4:30PM CDT
Amgen hasn't put as many eggs into the megablockbuster basket as Merck or Bristol-Myers Squibb , nor has it sought to utterly dominate a therapeutic area the way Biogen Idec may dominate MS. What Amgen does offer, though, is a deep pipeline... (full story)

Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer
PR Newswire - Mon Jun 16, 3:03PM CDT
Amgen (NASDAQ:AMGN) announced today that it will collaborate with the National Cancer Institute (NCI), part of the National Institutes of Health, and other public and private sector partners on the Lung Master Protocol (Lung-MAP), a groundbreaking new clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles. Lung-MAP is the first trial of its kind to study a large number of rare lung cancer subsets under one trial protocol. (full story)

Groundbreaking Collaborative Clinical Trial Launched
PR Newswire - Mon Jun 16, 8:00AM CDT
A unique public-private collaboration among the National Cancer Institute (NCI), part of the National Institutes of Health, SWOG Cancer Research, Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca's global biologics R&D arm, MedImmune), and Foundation Medicine today announced the initiation of the Lung Cancer Master Protocol (Lung-MAP) trial. (full story)

Is Gene Therapy Medicine's Next Big Thing?
Todd Campbell, The Motley Fool - Motley Fool - Sat Jun 14, 12:05PM CDT
Bluebird Bio is a small company with big ideas. The clinical stage biotechnology company is researching novel treatments that seek to insert missing genes into patient stem cells. The science behind  Bluebird's approach is so compelling that ... (full story)

The Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and Amgen
PR Newswire - Fri Jun 13, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the China Mobile Limited (NYSE:CHL-Free Report), China Petroleum and Chemical Corp. (NYSE:SNP-Free Report), Trina Solar Limited (NYSE:TSL-Free Report), AstraZeneca (NYSE:AZN-Free Report) andAmgen (Nasdaq:AMGN-Free Report). (full story)